Longeveron LLC

Yahoo Finance • 6 days ago

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsCle... Full story

Yahoo Finance • 24 days ago

Longeveron appoints interim CEO

* Longeveron (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]) appointed Than Powell as interim chief executive officer, effective immediately. * Powell replaces Wa’el Hashad. * Company founder and chief science officer Joshua Har... Full story

Yahoo Finance • 24 days ago

Longeveron® Announces Key Leadership Updates

Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa’el Hashad to step down as CEO and Bo... Full story

Yahoo Finance • last month

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions... Full story

Yahoo Finance • last month

These stocks have an unusual volume in today's session

These stocks have an unusual volume in today's session [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADD [https://www.chartmill.com/stock/quote/ADD/profile] -9.78% The trading volume of COLOR STAR TECHNO... Full story

Yahoo Finance • last month

Longeveron reports Q2 results

* Longeveron press release [https://seekingalpha.com/pr/20200156-longeveron-announces-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]): Q2 GAAP EPS of -$0.33 beats b... Full story

Yahoo Finance • last month

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are antici... Full story

Yahoo Finance • 2 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chro... Full story

Yahoo Finance • 2 months ago

Top stock movements in today's session.

Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT MRM... Full story

Yahoo Finance • 2 months ago

Longeveron Announces Up To $17.5 Million Public Offering

MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chro... Full story

Yahoo Finance • 2 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions... Full story

Yahoo Finance • 2 months ago

Which stocks are moving after the closing bell on Monday?

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT ADAP [https://www.... Full story

Yahoo Finance • 2 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent... Full story

Yahoo Finance • 3 months ago

Longeveron receives FDA approval for pediatric heart therapy IND

MIAMI - Longeveron Inc. (NASDAQ:LGVN), a clinical-stage biotechnology company with a current market capitalization of $19.4 million, has received U.S. Food and Drug Administration (FDA) approval for its Investigational New Drug (IND) appli... Full story

Yahoo Finance • 3 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies affect at least 100,000... Full story

Yahoo Finance • 3 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular t... Full story

Yahoo Finance • 3 months ago

Longeveron completes enrollment in HLHS pediatric heart trial

MIAMI - Longeveron Inc. (NASDAQ:LGVN), a clinical-stage biotechnology company with a market capitalization of $17.3 million and currently trading near its 52-week low, has completed enrollment for its Phase 2b clinical trial evaluating lar... Full story

Yahoo Finance • 3 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS I... Full story

Yahoo Finance • 4 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announce... Full story

Yahoo Finance • 4 months ago

Longeveron® to Attend BIO International Convention 2025

Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s diseaseRecent Type B meeting with FDA provided alignment on a planned single, pivotal Phase 2/3 clinical trial, which if... Full story